Lineage Cell Therapeutics (LCTX) EBITDA (2010 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly EBITDA of -$7.6 million for Q1 2026, down 16.73% year-over-year from -$9.1 million in Q1 2025, and down 15.96% quarter-over-quarter from -$6.5 million in Q4 2025.
Lineage Cell Therapeutics (LCTX) EBITDA (2010 - 2026) Analysis & Trends
Lineage Cell Therapeutics' EBITDA history runs 17 years deep, the most recent figure standing at -$7.6 million for Q1 2026.
- In Q1 2026, EBITDA fell 16.73% year-over-year to -$7.6 million; the TTM figure through Mar 2026 stood at -$37.7 million (down 76.85% YoY), while the FY2025 annual figure was -$36.6 million, down 70.5% from the prior year.
- EBITDA for Q1 2026 stood at -$7.6 million, down from -$6.5 million in the prior quarter.
- The five-year high for EBITDA was -$3.8 million in Q3 2025, with the low at -$19.8 million in Q2 2025.
- The 5-year median for EBITDA is -$6.4 million (2022), against an average of -$6.6 million.
- The sharpest annual moves came in 2022 and 2025: EBITDA jumped 76.49% in 2022, then plunged 237.14% in 2025.
- Lineage Cell Therapeutics' EBITDA stood at -$6.6 million in 2022, then increased by 4.17% to -$6.4 million in 2023, then climbed by 19.68% to -$5.1 million in 2024, then dropped by 28.14% to -$6.5 million in 2025, then slipped by 15.96% to -$7.6 million in 2026.
- Business Quant data shows LCTX's EBITDA at -$7.6 million in Q1 2026, -$6.5 million in Q4 2025, and -$3.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -8.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -8.92 Mn |
| Mar 31, 2026 | -7.59 Mn |
| Dec 31, 2025 | -6.55 Mn |
| Sep 30, 2025 | -3.79 Mn |
| Jun 30, 2025 | -19.78 Mn |
| Mar 31, 2025 | -6.51 Mn |
| Dec 31, 2024 | -5.11 Mn |
| Sep 30, 2024 | -3.84 Mn |
| Jun 30, 2024 | -5.87 Mn |
| Mar 31, 2024 | -6.66 Mn |
| Dec 31, 2023 | -6.36 Mn |
| Sep 30, 2023 | -6.71 Mn |
| Jun 30, 2023 | -5.02 Mn |
| Mar 31, 2023 | -6.64 Mn |
| Dec 31, 2022 | -6.64 Mn |
| Sep 30, 2022 | -5.25 Mn |
| Jun 30, 2022 | -4.23 Mn |
| Mar 31, 2022 | -6.40 Mn |
| Dec 31, 2021 | -28.24 Mn |
| Sep 30, 2021 | -6.84 Mn |